The plasma protease C1-inhibitor market size was valued at USD 4.18 billion in 2024 and is expected to reach USD 9.06 billion by 2032, growing at a CAGR of 10.15% over the forecast period of 2025-2032.
The plasma protease C1-inhibitors market is seeing dynamic expansion driven by rising incidence and better detection of hereditary angioedema (HAE) and other complement system diseases.
For instance, the U.S. National Institutes of Health estimates that HAE affects roughly 1 in 50,000 individuals worldwide; the Centers for Disease Control and Prevention (CDC) notes continuous attempts to enhance rare disease surveillance.
Rising global incidence and better identification of hereditary angioedema (HAE), an uncommon but sometimes life-threatening disorder characterized by swelling caused by C1-inhibitor deficiency, are the main forces behind the plasma protease C1-inhibitor market. To address unmet requirements in rare disease medicines, regulatory authorities, including the FDA and EMA, have sped approvals for C1-inhibitor medications, including orphan drug designations. Through institutions such as the NIH and FDA, the U.S. government has given rare disease research top priority and expeditious regulatory approval for C1-inhibitor drugs, including recombinant and plasma-derived medicines.
The U.S. plasma protease C1-inhibitor market size valued USD 1.24 billion in 2024 and is expected to reach USD 2.66 billion by 2032 with a CAGR of 10.03% over the forecast period 2025–2032. This is underlined by high awareness among healthcare professionals, advanced diagnosis capabilities, and strong support for clinical trials in HAE treatment. Further driving market expansion and availability are the FDA's orphan medication classification and new approvals for C1 esterase inhibitor treatments, including CINRYZE for pediatric and adult prophylactic therapy. Supported by government funding for rare illness therapies and continuous observation of complement system dysregulation, the move toward preventative treatment for HAE and acute HAE attacks shapes the market.
Drivers
Increasing Global Hereditary Angioedema Burden and Diagnostic Advancements Energy Need
A main driver of the plasma protease C1-inhibitor market is the rare genetic condition known as hereditary angioedema (HAE), which affects around 1 in 50,000 people globally. Improved diagnosis tools, including genetic testing and biomarker identification, have helped to lower misdiagnosis rates historically connected to HAE's vague symptoms, such as stomach pain or airway inflammation. Early discovery has been further enhanced by growing awareness efforts by groups such as the US Hereditary Angioedema Association and worldwide patient advocacy organizations, therefore facilitating early care. More individuals are so found and given C1-inhibitor treatments, which remain the gold standard for stopping and managing acute HAE events.
The creation of recombinant C1-inhibitors, such as conestat alfa, has further increased therapy choices by providing alternatives to drugs produced from plasma and thereby resolving issues around pathogen transmission. Furthermore, regulatory approvals for prophylactic use, best shown by the FDA's approval of Haegarda, have expanded the therapy's application, lowering hospitalization rates and enhancing quality of living. Demand is further driven by emerging economies in Asia-Pacific and Latin America, where better healthcare infrastructure is driving increased rates of HAE diagnosis. These elements together influence pharmaceutical investments in pipeline developments and manufacturing scaling, therefore guaranteeing continuous plasma protease C1-inhibitor market growth.
Restrain
Exorbitant Treatment Costs and Inequitable Reimbursement Limit Patient Access
The high costs of the therapies annual treatment charges typically surpass USD 500,000 per patient causing great limitations on the plasma protease C1-inhibitors market. While recombinant versions need complicated technological infrastructure, plasma-derived products need expensive manufacturing processes involving donor screening, pathogen inactivation, and cold-chain logistics. Many healthcare systems, especially in low- and middle-income countries, lack strong reimbursement systems, thereby requiring patients to pay outrageous out-of-pocket expenses. Notwithstanding clinical guidelines suggesting its use, coverage gaps for off-label uses or preventive regimens still exist even in developed areas such as Europe. This financial load causes therapy termination or reliance on less effective substitutes with side effects, such as testosterone or antifibrinolytics.
Moreover, differences in insurance policies, such as prior permission restrictions and limited qualifying criteria, increase access difficulties. For instance, with about 10–15% of HAE patients in India getting C1-inhibitors, low knowledge and poor insurance coverage cause underutilization. Programs of patient help by manufacturers still fall short in terms of scope to close these gaps. Because of patent protections and the intricacy of biologics, there is little generic competition, which helps to explain high prices. The market's expansion will stay limited to high-income areas without systematic modifications to pricing models, reimbursement regulations, and healthcare equity projects, therefore leaving a great unmet demand in underprivileged populations.
By Drug Class
Leading the market with 53.14% of the global revenue in 2024 are C1-inhibitors. The prevalence of the C1-inhibitor medicine class is based on proven efficacy for both acute and prophylactic management of hereditary angioedema. Human plasma-derived C1-inhibitor and recombinant C1-inhibitor treatments define most management of complement system inhibitor illnesses.
For instance, reflecting the FDA's regulatory focus on extending access to efficient treatments for all age groups, CINRYZE (C1 esterase inhibitor [human]) gained enhanced marketing approval in June 2025 for routine prophylaxis in pediatric HAE patients.
Supported by Takeda, this regulatory landmark highlights the need of plasma-derived C1-inhibitor and recombinant C1-inhibitor products in treating edema resulting from C1-inhibitor deficiency.
Due to their higher purity, lower danger of bloodborne pathogen transmission, and continuous supply, plasma protease C1-inhibitor market trends show a change from plasma-derived to recombinant C1-INH products. Key Plasma Protease C1-inhibitor businesses showing this change in ongoing investments are CSL Behring, Shire/Takeda, and Pharming Group, who are expanding their portfolios to include next-generation recombinant medicines. Rising availability of recombinant C1-inhibitor medications is driving market expansion, and patient outcomes are increasing according to the worldwide plasma protease C1-inhibitor market report.
Targeting the plasma kallikrein pathway, which is crucial in the pathogenesis of HAE attacks, the selective bradykinin B2 receptor antagonist segment is predicted to develop quickest over the projection period. At the AAAAI/WAO Joint Congress in March 2025, Pharvaris presented long-term clinical data showing that, in preventive settings, deucritibant, an oral bradykinin B2 receptor antagonist, achieved a median of zero days with attack symptoms per month, thus increasing health-related quality of life. These results from significant Phase 3 clinical studies in both preventative and on-demand settings show the potential of oral therapies to satisfy unmet goals for speedy and complete symptom relief in acute HAE episode therapy.
By Distribution Channel
Hospital pharmacies lead with 48% in the plasma protease C1-inhibitor market share. Especially for patients requiring immediate management of HAE or those on lyophilized formulations, hospital pharmacists remain the primary source of C1 inhibitor drug delivery. Reflecting the need for specialized handling and monitoring of complement system inhibitor medications, the U.S. Centers for Medicare & Medicaid Services (CMS) said that in 2024, over 60% of HAE treatments were delivered via hospital pharmacies. This channel facilitates the safe implementation of both recombinant C1-inhibitor therapies and plasma-derived ones, especially in acute care settings. Recently, government initiatives have greatly advanced hospital pharmacy infrastructure.
For instance, in January 2025 the U.S. Department of Health and Human Services (HHS) launched a funding program aimed at improving access to rare disease therapies, including C1 inhibitor therapy, in hospital contexts.
Driven by the digital health revolution, streamlined regulatory approval for C1-inhibitor drugs, and increasing demand for home-based care, online pharmacies are predicted to demonstrate the fastest CAGR. The FDA's 2024 update on telehealth and specialty pharmacy regulations allowed direct-to-patient shipment of C1 esterase inhibitor market products, therefore guaranteeing strict storage and handling standards. This regulatory shift has made drugs, including oral bradykinin B2 receptor antagonist and subcutaneous C1-inhibitor, more readily available to patients, especially for long-term preventative treatment for HAE.
By Dosage Form
With a revenue share of 56% in 2024, the lyophilized category leads the market. Lyophilized C1-inhibitor formulations are preferred for their stability, long shelf life, and simplicity of global distribution.
For instance, lyophilized 58% of all C1-inhibitor units acquired by U.S. public hospitals based on the 2024 annual report of the U.S. Pharmacopeia, which reflects great institutional confidence in this dose form.
The U.S. Department of Veterans Affairs (VA) added more lyophilized C1-inhibitor medicines to its list in February 2025, citing logistical advantages and patient preference for stable, easily reconstituted therapies.
Throughout the projection, the injectable segment is expected to show significant growth. Innovations in delivery devices such as pre-filled syringes and auto-injectors, which improve patient autonomy and adherence, are responsible for the increase. A first in complement system inhibitor self-administration, the FDA approved a novel subcutaneous C1-inhibitor auto-injector for home-based treatment in June 2025. Published in March 2025, a government-funded study showed patients utilizing the novel device had a 20% improvement in quality of life and a 30% decrease in treatment-related problems compared to conventional intravenous C1-inhibitor infusions. These results have led to revisions in state Medicaid coverage, therefore improving patient access to the newest injectable formulations.
Regional Analysis:
With a 38% of plasma protease c1-inhibitor market share in 2024, North America is still the dominating region; the U.S. plasma protease c1-inhibitor market was valued at over USD 1.24 billion in 2024 and expected to reach USD 2.66 billion by 2032, so exhibiting a strong CAGR of 10.03% over the forecast period, driven by variations in healthcare infrastructure, disease frequency, and regulatory backing, the plasma protease C1-inhibitor market growth shows distinct patterns across global regions.
High incidence of hereditary angioedema (HAE), sophisticated healthcare systems, and the presence of major plasma protease c1-inhibitor market companies such as CSL Behring, Takeda, and Pharming Group define this leadership. Strong regulatory systems and large investments in clinical trials and rare disease treatments help the U.S. as well to guarantee early acceptance of innovative therapies.
Europe held significant share of the global plasma protease c1-inhibitor market in 2024. Especially noteworthy for their quick acceptance of recombinant C1-inhibitor treatments and higher investment in gene therapy and antisense oligonucleotides are the UK and France. Rising healthcare costs, technology developments, and thorough reimbursement systems, which help access to both plasma-derived and recombinant C1-inhibitor products also drive Europe's growth.
With a projected CAGR of 10.67% from 2025 to 2032, the Asia Pacific region is experiencing the fastest market expansion. Rising incidence of chronic inflammatory disorders, an aging population, and increasing need for new therapeutic possibilities drive this increase. Countries including China are expected to grow at a significant CAGR, and Japan are actively investing in healthcare infrastructure and R&D. New participants and creative medication delivery techniques also help to explain the regions dynamic growth.
Supported by government programs to enhance rare disease detection and access to C1 inhibitor therapy, the LAMEA (Latin America, Middle East, and Africa) region is seeing consistent increase. Reflecting the effect of focused funding for rare disease treatments, Saudi Arabia's Ministry of Health noted a 15% rise in therapy use in 2024.
The key plasma protease C1-inhibitor companies are Takeda Pharmaceutical Company, BioCryst Pharmaceuticals, Pharvaris, Fresenius Kabi, CSL Behring, Ionis Pharmaceuticals, KalVista, Astria, Pharming, Sanquin, and others.
In May 2024, KalVista Pharmaceuticals announced its fiscal 2025 strategy, With an eye toward regulatory filings and commercialization plans for its oral therapy candidate for hereditary angioedema (HAE).
In June 2024, BioCryst Pharmaceuticals reported that Once-daily oral therapy with berotralstat greatly lowered monthly attack rates in hereditary angioedema (HAE) patients with normal C1-inhibitor levels.
Pharvaris presented long-term clinical results at the AAAAI/WAO Joint Congress in March 2025, proving the safety and effectiveness of oral selective bradykinin B2 receptor antagonist deucractibant for both preventative and on-demand treatment of HAE attacks. With a median of 0 days with attack symptoms each month, the crucial Phase 3 investigations revealed fast and total symptom relief.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 4.18 Billion |
| Market Size by 2032 | USD 9.06 Billion |
| CAGR | CAGR of 10.15% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (C1-inhibitors, C1-esterase Inhibitor, Kallikrein Inhibitor, Recombinant Inhibitor, and Selective Bradykinin B2 Receptor Antagonist) • By Dosage Form (Injectables, and Lyphophlised) • By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Takeda Pharmaceutical Company, BioCryst Pharmaceuticals, Pharvaris, Fresenius Kabi, CSL Behring, Ionis Pharmaceuticals, KalVista, Astria, Pharming, Sanquin, and others |
Ans. The projected market size for the Plasma Protease C1-inhibitor Market is USD 9.06 billion by 2032.
Ans: The North America region dominated the Plasma Protease C1-inhibitor Market in 2024.
Ans. The CAGR of the Plasma Protease C1-inhibitor Market is 10.15% during the forecast period of 2025-2032.
Ans: Exorbitant treatment costs and inequitable reimbursement limit patient access.
Ans: The Hospital Pharmacies segment dominated the Plasma Protease C1-inhibitor Market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Hereditary Angioedema (HAE), 2024
5.2 Prescription Trends by Region, 2024
5.3 Healthcare Spending by Source (Government, Insurance, Out-of-Pocket), 2024
5.4 Market Access and Reimbursement Trends
5.5 Pipeline and Regulatory Developments
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Plasma Protease C1-inhibitor Market Segmentation By Drug Class
7.1 Chapter Overview
7.2 C1-inhibitors
7.2.1 C1-inhibitors Market Trends Analysis (2021-2032)
7.2.2 C1-inhibitors Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 C1-esterase Inhibitor
7.3.1 C1-esterase Inhibitor Market Trends Analysis (2021-2032)
7.3.2 C1-esterase Inhibitor Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Kallikrein Inhibitor
7.4.1 Kallikrein Inhibitor Market Trends Analysis (2021-2032)
7.4.2 Kallikrein Inhibitor Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Recombinant Inhibitor
7.5.1 Recombinant Inhibitor Market Trends Analysis (2021-2032)
7.5.2 Recombinant Inhibitor Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Selective Bradykinin B2 Receptor Antagonist
7.6.1 Selective Bradykinin B2 Receptor Antagonist Market Trends Analysis (2021-2032)
7.6.2 Selective Bradykinin B2 Receptor Antagonist Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Plasma Protease C1-inhibitor Market Segmentation By Dosage Form
8.1 Chapter Overview
8.2 Injectables
8.2.1 Injectables Market Trend Analysis (2021-2032)
8.2.2 Injectables Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Lyphophlised
8.3.1 Lyphophlised Market Trends Analysis (2021-2032)
8.3.2 Lyphophlised Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Plasma Protease C1-inhibitor Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Online Pharmacies
9.3.1 Online Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Retail Pharmacies
9.4.1 Retail Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.4 North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.2.5 North America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.6.2 USA Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.2.6.3 USA Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.7.2 Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.2.7.3 Canada Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.2.8.2 Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.2.8.3 Mexico Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.4 Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.5 Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.6.2 Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.6.3 Germany Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.7.2 France Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.7.3 France Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.8.2 UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.8.3 UK Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.9.2 Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.9.3 Italy Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.10.2 Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.10.3 Spain Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.11.2 Poland Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.11.3 Poland Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.12.2 Turkey Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.12.3 Turkey Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.4 Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.5 Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.6.2 China Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.6.3 China Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.7.2 India Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.7.3 India Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.8.2 Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.8.3 Japan Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.9.2 South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.9.3 South Korea Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.10.2 Singapore Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.10.3 Singapore Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.11.2 Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.11.3 Australia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.6.2 UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.6.3 UAE Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Saudi Arabia
10.5.8.1 Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.8.2 Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.8.3 Saudi Arabia Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 Qatar
10.5.9.1 Qatar Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.9.2 Qatar Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.9.3 Qatar Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 South Africa
10.5.10.1 South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.10.2 South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.10.3 South Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.11 Rest of Middle East & Africa
10.5.11.1 Rest of Middle East & Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.5.11.2 Rest of Middle East & Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.5.11.3 Rest of Middle East & Africa Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.4 Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.6.5 Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.6.2 Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.6.6.3 Brazil Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.7.2 Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.6.7.3 Argentina Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Drug Class (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Dosage Form (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Plasma Protease C1-inhibitor Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 Takeda Pharmaceutical Company
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 BioCryst Pharmaceuticals
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Pharvaris
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Fresenius Kabi
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 CSL Behring
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Ionis Pharmaceuticals
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 KalVista
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 Pharming
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 Astria
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Sanquin
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Drug Class
C1-inhibitors
C1-esterase Inhibitor
Kallikrein Inhibitor
Recombinant Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage Form
Injectables
Lyphophlised
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
